✉news HealthMedicine first seen 4 d ago, last 3 d ago, peak #2
Base Editor Restores Glucose Production in GSDIa Patients
Researchers report that a base editing approach has restored glucose production in patients with glycogen storage disease type Ia, a rare metabolic disorder that causes severe hypoglycemia. If confirmed, the advance would mark a significant step for in vivo gene editing therapies for rare metabolic diseases, though details on trial size, safety and durability of the effect remain limited in early coverage.
Why now: A gene-editing therapy showing clinical benefit in a rare metabolic disease is a notable milestone that draws attention from the medicine and biotech community.
CRISPR base editingglycogen storage disease type Ia
Rank over time, top of the chart is #1. 7 snapshots from 4 d ago to 3 d ago.
Evidence
- Base Editor Restores Glucose Production in GSDIa Patients · CRISPR Medicine News
API: https://socialmediatrends-api.osmike.com/v1/trends/2235078